MMP13 and psoriatic arthritis: A set of biomarkers, composed matrix metalloproteinases, and their tissue inhibitors comprises MMP2, MMP12, MMP13, TIMP2, and TIMP4 whose circulating levels are higher psoriasis undergoing systemic therapy compared to the parallel with psoriatic arthritis cohort [47].